Genmab

GMABApproved

Genmab is a leading biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has established itself as a pioneer in antibody engineering with proprietary technology platforms including DuoBody and HexaBody. Genmab has multiple approved products generating significant revenue and maintains strategic partnerships with major pharmaceutical companies including Janssen, AbbVie, and Roche.

Market Cap

$15.4B

Employees

1,500-2,000

Focus

Biologics

GMAB · Stock Price

USD 25.1010.04 (-28.57%)

Historical price data

AI Company Overview

Technology Platform

Proprietary antibody engineering platforms including DuoBody (bispecific antibodies) and HexaBody (enhanced ADCC) technologies for creating differentiated cancer therapeutics.

Pipeline Snapshot

52 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Ofatumumab	Leukaemia, Lymphocytic, Chronic	Approved
Rina-S + Bevacizumab	Ovarian Cancer	Phase 3
Acasunlimab + Pembrolizumab + Docetaxel	PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	Phase 3
Zalutumumab	Head and Neck Cancer	Phase 3
Epcoritamab + Cyclophosphamide + Rituximab + Vincristine + Doxorubicin + Prednis...	Diffuse Large B-Cell Lymphoma	Phase 3

Funding History

Total raised: $595M

PIPE$500MBlackRockJul 15, 2020

IPO$60MMorgan StanleyOct 6, 2000

Series A$25MIndex VenturesJun 15, 2000

Seed$10MUndisclosedJun 15, 1999

FDA Approved Drugs

EPKINLYBLAMay 19, 2023

Opportunities

Significant growth potential from advancing pipeline programs including talquetamab in Phase 3, expanding approved product indications, and leveraging proprietary DuoBody and HexaBody platforms for new partnership opportunities in the large oncology market.

Risk Factors

Key risks include clinical trial failures in the competitive oncology space, regulatory delays for pipeline programs, dependence on pharmaceutical partners for commercialization execution, and potential market volatility affecting biotech valuations.

Competitive Landscape

Competes in the highly competitive antibody therapeutics space against established players like Roche/Genentech, Bristol Myers Squibb, and Regeneron. Genmab differentiates through proprietary bispecific and enhanced antibody platforms and successful partnership strategy that reduces development risk while maintaining upside potential.

Publications

Patents

Pipeline

FDA Approvals